You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. LystaMab Immunotherapy to Inhibit Pericardial Adhesions

    SBC: LYST THERAPEUTICS LLC            Topic: NHLBI

    SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Innovative 3D Printed Intravaginal Ring AnelleO-PRO, the first Single Administration of Progesterone for Infertility

    SBC: Anelleo, Inc.            Topic: NICHD

    Infertility is a global health problemand in the USmillion women are treated for infertility every yearThere is a strong need to promote patient friendly methods for progesterone supplementation in assisted reproductive technologyARTIntravaginal rings are well tolerated by womenare efficacious for contraception and hormone replacement therapyhave high patient complianceand are now in development f ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. A recombinant matrix to improve autologous tissue grafts

    SBC: inSoma Bio Inc            Topic: 102

    Abstract The objective of this proposal is to validate a new regenerative tissue matrix which studies to date indicate may be possible of redefining the limits of autologous fat graftingThis objective is motivated by the currently limited surgical options available to themillion patients undergoing reconstructive plastic surgery each year to treat body disfigurement and dysfunctionA core component ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Science Take-Out Kits for Improving Environmental Health Literacy on Vaping

    SBC: Science Take-Out, LLC            Topic: R

    ABSTRACT This supplement project will expand on our current STTR Phase I project in which we partnered with University of Rochesterandapos;s Environmental Health Sciences Center to develop three Science Take-Out vaping education kits. Our vaping education kits involve students in using hands-on activities and real-life scenarios to investigate the harmful effects of chemicals used in e-cigarette f ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Rapid High-Fidelity Assembly of Challenging Peptide Sequences

    SBC: VELUM INC            Topic: NIGMS

    PROJECT SUMMARY Peptide therapeutics combine high potency and selectivity with fewer side effects than traditional small moleculesThis has fueled interest in peptides filling the gap betweenbiologicsand small molecules as compounds that have the key desired properties from both the other classesWorldwide peptide drug sales surpassed $billion inof which nearly $billion was in the USAwith projected ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Discovery of TrkC agonist antibodies for hearing loss

    SBC: ZEBRA BIOLOGICS INC            Topic: NIDCD

    ! Project Summary AbstractSensori neural hearing lossSNHLis caused by several factorsincluding excessive noisedrug toxin exposure and genetic lesionsTaken togetherhearing deficits represent the number one neurological disorder worldwideDespite numerous past and ongoing clinical studies there is currently no effective therapeutic treatment for hearing loss and its associated decline in quality of l ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Regenerative rotator cuff repair in a clinically relevant chronic disease model

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    ABSTRACT Rotator cuff repairRCRis a common first line surgical solution to symptomatic rotator cuff injurywith overRCRs performed annuallyand growing at a rate ofUnfortunatelyof the cases are complicated by failure and re tear of the repaired tendonwhich commonly results in a significant reduction in activities of daily livingworkand or sports and recreation for the patient due to pain and restric ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Improving ALS Diagnosis using Needle I-EMG

    SBC: Haystack Diagnostics, Inc.            Topic: 103

    PROJECT SUMMARY Needle electromyographyEMGremains the standard approach for assessing neuromuscular diseaseWhile the technique has proven to be clinically valuable over the lastyearsit has important limitationsThese include its not being sensitive to alterations in muscle composition and structureits inability to assess the contractile apparatus of muscleand its subjective nature with an inter rat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.

    SBC: BIOMIMETIX JV LLC            Topic: 102

    Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government